Skip to main content
Shan Lu

Shan Lu

Worcester HIV Vaccine
United States

Shan Lu is a physician scientist and global leader in vaccine science with significant experience in managing large multi-institute biomedical research and product development programmes in the field of novel vaccines.

Shan is a full Professor with tenure and, since 1996, has been Director of the Laboratory of Nucleic Acid Vaccines in the Department of Medicine, University of Massachusetts Medical School, USA.

He was an early pioneer in nucleic acid vaccines (DNA and RNA) in the early 1990s and has advocated for advancement of this field. He promoted the heterologous prime-boost vaccination concept and developed the world's first polyvalent DNA/protein HIV vaccine into human clinical studies, which showed robust and broadly cross-reactive immune responses. He has over 200 publications in leading scientific journals and co-authored over 10 specialty books.

He is a US board-certified physician in internal medicine with 20 years’ clinical practice experience. Shan has direct management experience of major NIH-funded vaccine development programmes, including GMP manufacturing and FDA IND filing. He has broad biotech industry collaboration and advisory activities.

Shan is the founding Editor-in-Chief of Emerging Microbes and Infections, a leading journal in infectious diseases published by Nature and Taylor & Francis. He is also an active member of the editorial boards for the Journal of Virology, Current Opinion of Virology, Vaccine, NPj Vaccine and Human Vaccines & Immunotherapeutics.

He has been a board member of the International Society for Vaccines (ISV) since 2008. He also served as ISV President for 2011-2013 and as a Co-Chair of the ISV Board of Directors. He served as chair or organized for a wide range of congresses over the past two decades. He is a Fellow of ISV and the America College of Physicians.

The IAS promotes the use of non-stigmatizing, people-first language. The translations are all automated in the interest of making our content as widely accessible as possible. Regretfully, they may not always adhere to the people-first language of the original version.